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Introduction
 Squamous cell carcinoma (SCC) is the most fre-
quently occurring cancer in the oral and maxillo-
facial region and its metastatic and invasive abil-
ity result in a poor prognosis.  The standard 
treatment for oral cancer is a combination of sur-
gery, radiation and chemotherapy.  To develop a 
novel effective therapy for oral cancer, a further 
understanding of the processes and molecules 
leading to initiation and progression of the condi-
tion are required. 
 Heparin-binding EGF-like growth factor (HB-
EGF), which belongs to the EGF family, was origi-
nally identiﬁed in the conditioned medium of a 
human histiocytic lymphoma cell line, U9371. 
Gene or protein expression of HB-EGF has been 
subsequently detected in various rat tissues2, 
smooth muscle cells and macrophages of human 
atherosclerotic plaques3, and gastric cells of the 
pyloric glands and parietal cells of the fundic 
glands in the human gastric mucosa4.  HB-EGF 
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Abstract : Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF), which be-
longs to the EGF family, has been shown to stimulate the growth of a variety of cells in an auto-
crine or paracrine manner.  Although HB-EGF is widely expressed in tumors when compared to 
normal tissue, its contribution to tumor invasion is still not known.  In the present study, we ana-
lyzed the effects of HB-EGF on the invasion activity of a cultured oral cancer cell line using short 
interfering RNA (siRNA).
 Oral squamous carcinoma cell lines, HSC3 and SAS, were transfected with siRNA targeting HB-
EGF. Expression of HB-EGF was analyzed by real-time PCR.  The invasiveness of the transfected 
cells was determined using a matrigel invasion assay, and MMP-9 production was measured by RT-
PCR and gelatin zymography.
 The expression of HB-EGF was reduced in HSC3-siRNA and SAS-siRNA cells.  The matrigel in-
vasion assay demonstrated that the invasiveness of HSC3-siRNA and SAS-siRNA cells was re-
duced.  Gelatin zymography demonstrated that in HSC3-siRNA and SAS-siRNA cells, MMP9 pro-
duction was decreased. 
 These ﬁndings suggest that HB-EGF expression is related to the invasion activity of oral cancer, 
particularly via regulation of MMP9.
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stimulates the growth of a variety of cells in an 
autocrine or paracrine manner.  When it binds to 
the EGF receptor (EGFR), it induces EGFR auto-
phosphorylation as well as a variety of other bio-
logical activities including proliferation and 
migration. Secreted mature HB-EGF is a potent 
mitogen for NIH-3T3 cells, bovine aortic smooth 
muscle cells (BASMC)5,6, rat hepatocytes7, human 
keratinocytes8, and rat gastric epithelial cells9. 
 HB-EGF has been identiﬁed as an immediate-
early response gene that can be activated though 
the Ras/Raf signaling pathway that mediates the 
autocrine activation of the c-Jun kinase in 
NIH3T3 cells10.  Ets-2 phosphorylation by activa-
tion of the Raf1/MAPK cascade regulates the 
induction of HB-EGF transcription in mouse ﬁbro-
blasts11.  Moreover, in nontransformed human 
mammary epithelial cells, HB-EGF expression is 
induced by EGF and Ha-Ras overexpression12, 
strongly suggesting that HB-EGF is a direct tar-
get of mitogen-activated protein kinase (MAPK). 
Several laboratories have described HB-EGF up-
regulation in response to oncogene expression as 
well as in oncogene-transformed cells13,14.  More-
over, HB-EGF expression has been implicated in 
tumor progression and invasion because of its 
overexpression in many tumors including hepato-
carcinoma, melanoma, as well as colon, breast, 
myeloma, prostate, and bladder tumors15–22.  It 
has also been implicated in increased proliferation 
and metastasis.  In the present study, we analyzed 
the effects of HB-EGF on the invasion activity of 
cultured oral cancer cell lines, HSC3 and SAS, 
using short interfering RNA (siRNA).
Material and Methods
1. Cell Culture and Transfection
 HSC3 and SAS cell lines were obtained from 
The Human Science Research Resource Bank 
(HSRRB, Osaka, Japan) and were maintained in a 
Minimum Essential Medium (MEM: Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin at 
37℃ in a humidiﬁed atmosphere of 95% air and 
5% CO2.
 HSC3 and SAS cell lines were transfected with 
HB-EGF siRNA oligos (Sense : 5'-GGACCCAUGU-
CUUCGGAAA-3', Antisense : 5'-UUUCCGAAGA-
CAUGGGUCC-3') and negative control siRNA oli-
gos (Sense : 5'-AUCCGCGCGAUAGUACGUA-3', 
Antisense : 5'-UACGUAGUAUCGCGCGGAU-3') 
(B-Bridge International, Mountain View, CA) 
using Lipofectamine RNAi MAX (Invitrogen, 
Carlsbad, CA) according to the manufacturer's 
instructions and incubated for 48 hr at 37℃ in a 
humidiﬁed atmosphere of 95% air and 5% CO2. 
 Experimental groups included HSC3-siRNA and 
SAS-siRNA transfectants, negative control trans-
fectants, and normal HSC3 and SAS cells.
2. Cell proliferation  assay
 MTT assay ; Cell viability of HSC3 and SAS, 
and HSC3-siRNA and SAS-siRNA, and HSC3 and 
SAS negative control transfectants was assessed 
by MTT assay performed at three time points (on 
day 1, 2 and 3) after the seeding.  Fifty microliters 
of MTT reagent added to each well of the plates 
and incubated for 1 hr at 37℃.  After the reaction, 
500 μl of isopropanol with 0.04 N HCl was added 
to each well. Each reaction was transferred into a 
96-well plate, and absorbance was measured at a 
test wavelength of 570 nm and a reference wave-
length of 630 nm with a Model 680 Microplate 
Reader (Bio-Rad).
3. RNA Isolation and quality measurement
 The total RNA of each sample was isolated 
using the Qiaquick RNeasy Mini kit (Qiagen, 
Valencia, CA) according to the manufacturer's 
instructions.  Brieﬂy, each sample was lysed in a 
lysis buffer with repetitive pipetting, and then 1 
volume of 70% EtOH was added and mixed imme-
diately by pipetting.  The mixture was transferred 
to an RNeasy mini column and centrifuged at 
12,000 xg for 15 seconds.  350 μl of Buffer RW1 
was added to the column and treated with RNase-
free DNase to digest contaminating genomic DNA. 
The DNase was washed away by adding another 
350 μl of Buffer RW1, and the column was then 
washed with 500 μl of Buffer RPE two times.  The 
eluted RNA was quantiﬁed using a ND-1000 spec-
trophotometer (NanoDrop Technologies, Inc., 
Wilmington, DE).  The quality of the RNA was 
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veriﬁed by an Agilent 2100 bio-analyzer (Agilent 
Technologies, Palo Alto, CA).
4. Real-time PCR
 Reverse transcription was performed with the 
TaqMan RT kit (Roche Diagnostics, Indianapolis, 
IN) according to the manufacturer's instructions. 
Brieﬂy, reverse transcription was carried out in a 
volume of 100 μl with 300 ng of the RNA sample, 
15 pmol of oligo deoxythymidine primers and ran-
dom primers, 10 μl of 10X TaqMan Buffer, 22 μl 
of 25mM MgCl2, 20 μl of each 2.5mM dNTP, 
RNase inhibitor, and reverse transcriptase.  RT 
conditions were as follows: 10 min at 25℃,  30 min 
at 48℃, and 5 min at 95℃.  Real-time PCR was 
performed in an ABI PRISM 7900HT machine 
(Applied Biosystems, Foster City, CA) using SYBR 
Green PCR Master Mix (Applied Biosystems, Fos-
ter City, CA), according to the manufacturer's 
instructions in a total volume of 25 μl.  Cycling 
conditions were 2 min at 50℃, 10 min at  95℃, 40 
cycles for 30 sec at 95℃, 30 sec at 58℃, and 1 min 
at 72℃.  To correlate the threshold (Ct) values 
from the ampliﬁcation plots to the copy number, a 
standard curve was generated and a non-template 
control was run with every assay. 
 We multiplied the normalized quantity by 103 
because all of the values were less than 1.  This 
format makes it easier to compare the values 
between all the samples through a graph.  
 Normalized expression quantity = 
 Mean of HB-EGF expression quantity / Mean of 
GAPDH expression quantity× 1,000.  
 Real-time PCR Primers were as shown in Table 
1.
5. Matrigel invasion assay
 Assays were performed according to the manu-
facturer's instructions.  Brieﬂy, cells (2× 104/well) 
were seeded in a 6-well BioCoat MATRIGEL Inva-
sion Chamber (BECTON DICKINSON, Bedford, 
MA, USA) in DMEM containing 10% (v/v) heat 
inactivated fetal calf serum.  After a 48 hr-incuba-
tion, noninvading cells were removed from the 
upper surface of the membrane by scrubbing, and 
the membrane was stained with a Diff-Quik stain 
kit.  Subsequently, the number of invading cells 
were counted using a microscope and the invasion 
index (=cells migrating through the Matrigel 
coated membrane/cells migrating through the con-
trol insert membrane) was  measured.
6. Zymogram
 SDS-substrate polyacrylamide gel electrophore-
sis (SDS-PAGE) was done with gels containing 
gelatin (0.1%) and 12.5% polyacrylamide.  After 
HSC3-siRNA and SAS-siRNA, control, and normal 
HSC3 cells and SAS cells were incubated in a 
serum-free medium for 48 hr, the medium super-
natants were aspirated and subjected to Zymo-
grams.   Samples were diluted in a SDS-PAGE 
sample buffer. Electrophoresis was carried out at 
60 mA at 4℃ for 2 hr, and then samples were incu-
bated overnight in 0.05M Tris/HC1 (pH 7.5) buffer 
containing 10M CaCl2.  Gels were stained with 
Coomassie Blue (0.25%) and de-stained in metha-
nol/acetic acid/water (50 :10 :40).
7. Statistical analysis
 The Mann-Whitney U-test was used to assess 
the statistical signiﬁcance of differences between 
the samples.  P values less than 0.05 were consid-
ered to indicate statistical signiﬁcance.
Table 1 PCR Primers sequences used in the real-time PCR and RT-PCR
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Results 
1.  Effect of HB-EGF on HSC3 and SAS cell 
proliferation
 The Mtt assay showed almost the same prolifer-
ation rate in HSC3-siRNA and SAS-siRNA cells 
compared with parental HSC3 and SAS cells, and 
the negative control transfections (Fig. 1). 
2.  Effect of HSC3-siRNA and SAS-siRNA 
treatment on HB-EGF mRNA expression
 To determine whether HSC3-siRNA and SAS-
siRNA cells had reduced levels of HB-EGF mRNA, 
the total RNA from HSC3-siRNA and SAS-siRNA 
cells was analyzed by real-time PCR. The amount 
of HB-EGF mRNA was signiﬁcantly reduced in 
the HSC3-siRNA and SAS-siRNA cells when com-
pared with the parental HSC3 and SAS cells, and 
the negative control transfections (Fig. 2). 
3.  Invasion activity of HSC3-siRNA and SAS-
siRNA cells
  Invasion activity of HSC3-siRNA and SAS-
siRNA cells was assayed in vitro using a matrigel 
invasion chamber. Both parental HSC3 and SAS 
cells and negative control transfectants were inva-
sive.  However, the invasiveness of HSC3-siRNA 
and SAS-siRNA cells was relatively low compared 
to parental and control cells (Fig. 3).  
4.  Reduction of MMP-9 expression in HSC3-
siRNA and SAS-siRNA cells
 We examined the effects of HSC3-siRNA and 
SAS-siRNA transfection on MMP9 mRNA expres-
sion uisng RT-PCR.  The amount of MMP9 mRNA 
was signiﬁcantly reduced in HSC3-siRNA and 
SAS-siRNA cells when compared to parental 
HSC3 and SAS and the negative control transfec-
tants (Fig. 4).  Next, we examined MMP9 produc-
tion with gelatin zymography.  Conditioned media 
from HSC3 and SAS, HSC3-siRNA and SAS-
Fig. 1 Effect of HB-EGF in HSC3 and SAS cell proliferation. The Mtt assay showed almost 
the same proliferation rate in HSC3-siRNA and SAS-siRNA cells compared with pa-
rental HSC3 and SAS cells, as well as the negative control transfections.
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Fig. 2 Expression of HB-EGF mRNA in HSC3-siRNAand SAS-siRNA cells as de-
termined by real-time PCR. The amount of HB-EGF mRNA was signiﬁ-
cantly reduced in HSC3-siRNA and SAS-siRNA cells when compared to pa-
rental HSC3 and SAS, as well as negative control cells. β-actin mRNA was 
used as an internal control for PCR.
Fig. 3 Invasion activity of HSC3-siRNA and SAS-siRNA cells as determined by matrigel inva-
sion chamber. Brieﬂy, cells (2× 104/well) were seeded in a 6-well BioCoat MATRIGEL 
Invasion Chamber (BECTON DICKINSON, Bedford, MA, USA) in DMEM containing 
10% (v/v) heat inactivated fetal calf serum. After a 48 hr incubation, noninvading cells 
were removed from the upper surface of the membrane by scrubbing, and the mem-
brane was stained with a Diff-Quik stain kit. Subsequently, the number of invading 
cells were counted using a microscope, and the invasion index (=cells migrating 
through Matrigel coated membrane/cells migrating through control insert membrane) 
was  measured. Both parental HSC3 and SAS　cells and negative control transfectants 
were highly invasive, but the invasiveness of HSC3-siRNA and SAS-siRNA transfectant 
was relatively low.
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siRNA cells, and negative control cells were sub-
jected to gelatin zymography.  HSC3-siRNA and 
SAS-siRNA cells showed less 92-kd collagenolytic 
activity than parental HSC3 and SAS, and the 
negative control cells, however, the effect of HSC3-
siRNA transfection on the production of pro-
MMP2 was negligible (Fig. 5).
Discussion
 HB-EGF is a member of the EGF family of 
growth factors that binds to and activates EGFR. 
HB-EGF is known to be a potent mitogen for kera-
tinocytes, hepatocytes, smooth muscle cells, and 
ﬁbroblasts23–25. 
 Moreover, HB-EGF expression is elevated in 
human cancers including gastric and hepatocellu-
lar  carcinoma, breast carcinoma, melanoma, pan-
creatic cancer, colon cancer, glioma, and glioblas-
toma18,19.  In this study, we used HSC3 and SAS, 
together with an invasive oral SCC-derived cell 
line, and investigated the inhibitory effects of HB-
EGF siRNA on invasive HSC3 and SAS cells.  The 
expression of HB-EGF was dramatically reduced 
in HSC3-siRNA and SAS-siRNA cells transfected 
with siRNA targeting HB-EGF.  Moreover, the 
matrigel invasion assay demonstrated that the 
invasiveness of HSC3-siRNA and SAS-siRNA cells 
was relatively lower than that of parental and 
control cells.  These ﬁndings suggest that HB-EGF 
siRNA can considerably control the permeation 
ability of HSC3 and SAS cells.
 MMPs are thought to play an important role in 
cancer invasion and metastasis26–28, as they 
degrade various types of collagen including 
stromal type 1 collagen and type 4 collagen of the 
basement membrane, as well as proteoglycans. 
Expression of matrix-degrading proteinases is ele-
vated in a variety of invasive carcinomas29,30.  It is 
now clear that up-regulation of MMP activity 
results in proteolytic degradation of the extracel-
lular matrix and the basement membrane, which 
in turn promotes tumor growth, angiogenesis, and 
Fig. 4 MMP9 expression as determined by RT-PCR. The amount of MMP9 mRNA was signiﬁcantly reduced in 
HSC3-siRNA and SAS-siRNA  cells when compared to parental HSC3 snd SAS cells, as well as negative con-
trol cells. β-actin mRNA was used as an internal control for PCR.
Fig. 5 Gelatin zymography. HSC3-siRNA and SAS-siRNA cells showed less 92-kd type collagenolytic activity 
than parental HSC3 and SAS cells or negative control transfectants, although the effect of HSC3-siRNA 
and SAS-siRNA transfection on the production of pro-MMP2 was negligible.
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metastasis.  However, the activation mechanisms 
of these invasion-associated genes are still not 
well understood.
 Next, we examined the mRNA and protein lev-
els of the extracellular matrix-degrading enzyme 
MMP9.  MMP9 mRNA levels were reduced in 
HSC3-siRNA and SAS-siRNA cells, which also 
showed a reduced amount of MMP9 protein when 
compared to parental HSC3 and SAS cells, as well 
as negative control cells. 
 These results indicate that HB-EGF siRNA 
treatment inhibited MMP9 gene expression, which 
then caused a reduction in MMP9 enzyme activity.
 Thus, the inhibition of HB-EGF expression 
caused MMP9 down-regulation, which then 
resulted in a reduction in the malignancy of can-
cer cells.  The biological behavior of HSC3 and 
SAS cells were remarkably altered by HB-EGF 
siRNA treatment.  Previous studies indicated a 
possible correlation between HB-EGF expression 
and the malignant phenotype of cancer cells, and 
also provided direct evidence that HB-EGF trans-
activates multiple metalloproteinase genes such 
as MMP9, thereby establishing an important role 
for HB-EGF in tumor invasion31.  Suppression of 
endogenous HB-EGF expression via siRNA knock-
down inhibited oral cancer invasion, which further 
supports the hypothesis that HB-EGF is a key 
molecule in the tumor-forming activity of oral can-
cer cells.
 The standard treatment for oral cancer is a 
combination of surgery, radiation  and chemother-
apy.  Cytotoxic agents including carboplatin, cispl-
atin and paclitaxel form the cornerstone of chemo-
therapy in oral cancer.  However, some patients 
with advanced oral cancer relapse and ultimately 
die due to the development of drug resistance.  In 
ovarian cancer, overexpression of EGFR has been 
associated with chemoresistance and poor progno-
ses32.  Targeting HB-EGF, an abundant EGFR 
ligand, may be favorable for treatment of 
chemoresistant oral cancer.  It has also been found 
that HB-EGF activates ErbB4 and ErbB2 as well 
as EGFR33.  Therefore, HB-EGF might be a better 
therapeutic target for oral cancer than EGFR. 
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